Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems develops and commercializes minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. Its proprietary Inspire therapy is approved by the FDA, EU MDR and PDMA for moderate to severe obstructive sleep apnea, and product updates include the Inspire V system.
Company news commonly covers quarterly and annual results, revenue guidance, cash flow, earnings measures, reimbursement and coding developments, product launch activity, regulatory clearances such as MRI compatibility, executive changes and healthcare conference presentations.
Inspire Medical Systems (NYSE: INSP) announced that its management team will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m. Eastern Time. The presentation will be available via live webcast with a two-week replay on Inspire’s investor website.
Mobia Medical (Nasdaq: MOBI) appointed Myriam Curet, M.D. to its Board of Directors as an independent director, effective July 30, 2026. The company highlights her combination of clinical, executive and public company board experience to support its stroke recovery business.
Dr. Curet is a Clinical Professor of Surgery at Stanford University School of Medicine, holds a part-time clinical role at the Palo Alto VA Medical Center, and has previously held senior surgical posts at Stanford and the University of New Mexico. She also serves on the boards of Inspire Medical Systems (NYSE: INSP) and Stereotaxis (NYSE American: STXS) and is a Fellow of the American College of Surgeons.
Inspire Medical Systems (NYSE: INSP) reported second quarter 2026 revenue of $200.6 million, down 7.6% year over year, with lower U.S. sales partly offset by international growth. Gross margin improved 150 bps to 85.5%. Operating loss narrowed to $0.5 million, with adjusted operating income of $3.2 million (1.6% margin). Net earnings were $0.3 million, or diluted EPS of $0.01, and adjusted diluted EPS was $0.14.
Operating cash flow rose to $23.2 million, and cash, cash equivalents, and investments were $415.2 million at June 30, 2026. The company raised 2026 revenue guidance to $835–$875 million, with expected adjusted operating margin of 4%–6%. Inspire also launched Project Horizon, a strategic growth plan expected to create about $30 million of annualized investment capacity, supported by $20–$25 million in projected pre-tax restructuring charges through 2026.
Inspire Medical Systems (NYSE: INSP), a medical technology company focused on minimally invasive treatments for obstructive sleep apnea (OSA), appointed seasoned medical device executive Michael H. Carrel to its Board of Directors, effective July 20. Chairman and CEO Tim Herbert said the company looks forward to his guidance as it advances Inspire therapy.
Carrel has served as President, Chief Executive Officer and director of AtriCure (NASDAQ: ATRC) since November 2012. Under his leadership, AtriCure’s revenue grew from $82 million in 2013 to $535 million in 2025, treating more than one million patients. He previously chaired the board of Axonics from 2019 to 2024, through its sale to Boston Scientific. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School. He cited Inspire’s fifth-generation device, product pipeline and growing evidence of long-term cardiovascular benefits as reasons he believes the company is well positioned to expand access for OSA patients.
Inspire Medical Systems (NYSE: INSP) announced that Casey M. Tansey will retire from its Board of Directors on July 30 after more than 18 years of service. Tansey, representing U.S. Venture Partners, led Inspire’s Series A financing in November 2007 and has served on the Board since then. The company expects to appoint a new director to replace him in the near future.
Inspire Medical Systems (NYSE: INSP) corrected its second quarter 2026 earnings release schedule. The company will now report results after market close on Monday, August 3, 2026, followed by a conference call at 5:00 p.m. Eastern Time.
Investors can join via webcast on the Investor Relations website or register for the live call to ask questions. A replay will be posted about two hours after the event and remain available for two weeks.
Inspire Medical Systems (NYSE: INSP) will release its second quarter 2026 financial results after the market close on Monday, August 3, 2026. Management will host a conference call at 5:00 p.m. Eastern Time, with access via webcast and phone registration links.
Inspire Medical Systems (NYSE: INSP) will showcase new clinical data and technology at SLEEP 2026 in Baltimore. Highlights include Inspire V system performance, cardiovascular outcomes research, and the publication of the PREDICTOR study.
Data cover hypoxic burden, long-term registry outcomes, and comparisons between hypoglossal nerve stimulation, CPAP, and no treatment.
Inspire Medical Systems (NYSE: INSP) announced that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on Friday, June 26, 2026. The company is scheduled to present at 10:00 a.m. Eastern Time, with a live webcast and two-week replay available.
Inspire Medical Systems (NYSE: INSP) reported Q1 2026 revenue of $204.6 million (up 1.6% YoY), GAAP diluted EPS of $(0.39) and adjusted diluted EPS of $0.10. Operating cash flow was $12.8 million and gross margin rose 180 bps to 86.5%. The company narrowed full‑year revenue guidance to $825–$875 million (down 4%–10% vs 2025) and expects adjusted diluted EPS of $0.75–$1.25, with an assumed adjusted tax rate of 27%–29%.
The company cited coding and reimbursement disruption and implementation of the WISeR program as near‑term headwinds and anticipates challenges to persist through 2026 while targeting a return to revenue growth in 2027.